Skip to main content
Presentation
Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the FUTURE 1 and FUTURE 2 studies. British Society for Rheumatology (BSR), Liverpool, May 2018.
British Society for Rheumatology (BSR) (2018)
  • H Chinoy
  • L Gossec
  • Philip Mease, Providence St. Joseph Health
Disciplines
Publication Date
May, 2018
Location
Liverpool
Citation Information
H Chinoy, L Gossec and Philip Mease. "Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the FUTURE 1 and FUTURE 2 studies. British Society for Rheumatology (BSR), Liverpool, May 2018." British Society for Rheumatology (BSR) (2018)
Available at: http://works.bepress.com/philip-mease/146/